ABC

A.

Cellular proteins

Immunoglobulin proteins

Inferred abundance in B cells proteome (PSMs per protein)

10000

HSP90AA1

HSP90AB1

HNRNPA2B1 LCP1

ACTBL2

MYH9

TUBB

HSPD1

Extracellular/plasma proteins ACTB HSPA8 VIM NCL CFL1

ENO1

1000

GPI NPC2 IL16

MZB1 TXLNA

100

HDGF

LGALS1

H2AFX HIST1H2BA

Hbb-b1 HBA1/HBA2 Prss1 Hbbt1

HA1

PSAP

SOD1

THBS1 MIF

GSN FGB

NENF GRN

C4A/C4B APOB SERPINA3

TGFBI PRL

HPX

PF4

1

1

DSC1

10

Pzp/A2M

AHSG SERPINC1

DDT

CLEC11A

APOA1 SERPINA1 SERPINA1

Ces1c

VTN

APOA4 E1PDR

ALB

APOE SNCA

MYDGF

Ccl6

C3

B2M

FN1

FGG

TGFB1

TF

LYZ FGA CST3

FAM3C

10

Hist1h4a H2AFZ

GAPDH

HSPA5

Ngp

IDE

HIST1H2BN

PPIA

HNRNPF

LTF

- (overrepresented in plasma)

Cellular proteins

Cytokines/Growth factors

Mug1

CFB

100

1000

10000

Inferred abundance in plasma proteome (PSMs per protein)

A. PSM-derived approximations of overall proteome abundances of the 1288 proteins identified for both plasma and B-cells. Proteins are highlighted based on canonical localisations or protein class and annotated based on inter-proteome differential abundance.

B.

Terminal plasma from both tumours ATP2B3

DSG2 Ighv1-5

CCDC113

ATP2C2

-1.8

-1.6

CELA2A CFD HLA-A KTDAP APOA2 RPS6 CHST2 AMBN ANKRD11 Gm10881

4.0

YTHDF2 Gm6346

3.5

-1.0

-0.8

3.0

4.0

3 2

193 proteins

1.301 (p=0.05)

CDYL

-1.2

CNBP RRBP1 TMX1 GRB2 S100A8 SC5AA AIMP2 PTN18 NAPSA S100A6 CCD23 PDS5A SAA3 UBL5 PSB10 NUCL PTMA HNRNPA0 MK67I ROA2 TR150 THUM1 SERF2 RL29 LSM8 L10K LSM7 NOVA2

4.5

4

APC TRIM65 TCEAL5 Apoc3 TMEM145

-1.4

5

4.5

CREB3L3

-3

-2

625 proteins

3.5

1

-1

0 -0.5

0

0.5

1

2

3

3.0

1.2

1.4

1.6

1.8

Regulation score (mean/SD+1) derived from log2 (ratios of tumour samples to WT samples)

C.

Underexpressed tumour proteins (402)

382

20

Underabundant 173 terminal plasma proteins (193)

Underabundant terminal Underabundant terminal Eµ-myc plasma Eµ-TCL1 plasma proteins (113) proteins (119) 70 43 76

Overexpressed Overabundant tumour proteins 1247 120 505 terminal plasma (1367) proteins (625)

Overabundant terminal Overabundant terminal Eµ-TCL1 plasma Eµ-myc plasma proteins (344) proteins (727) 448 279 65

B. Volcano plots highlighting the most significantly differentially abundant plasma proteins in the terminal plasma of both tumours. The number of significantly (p0.5) and under-abundant (Rs0.5/0.3) for each model. E. Those proteins commonly identified in the B-cell tumour proteome F. Those proteins not attributable to tumour lysis, based on extracellular localisation.

G. The top 30 overabundant proteins in terminal plasma from both tumours, detailing the respective B-cell proteome quantitations for those proteins commonly identified. Proteins with a canonical localisation as either cytoplasmic or nuclear are highlighted. H. The top 25 overabundant terminal plasma proteins with IPA-annotated biomarker applications. I. The top 20 proteins most overabundant in pre-terminal, early-tumour ‘30%’ Eµ-TCL1 plasma, with any IPA-annotated biomarker applications noted. J-P. Correlative plasma signatures of tumour-derived biomarkers from tumour lysis products, protein secretion and shedding. Proteins were filtered on the basis of regulation score (±0.5) and significance (p0.5, p